SCHEMBL273450

SCHEMBL273450

CCCC#COS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 1/20 0.40
HSP90AA1 P07900 1/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
XBP1 P17861 1/20 0.40
MAPK1 P28482 1/20 0.40
MPI P34949 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GAA P10253 2/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17891971 0.86 ALDH1A1 (0.42) CA12CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL28977454 0.85 PSIP1 (0.42) ALDH1A1SMN1; SMN2LMNAHSP90AA1MAPT
Acetic Acid SCHEMBL30040945 0.80 KMT2A (0.41) ALDH1A1SMN1; SMN2LMNAHSP90AA1MAPT
SCHEMBL7624623 0.79 CA12 (0.40) CA12CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL14997649 0.79 CA12 (0.40) CA12CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL5332415 0.77 GAA (0.46) CA12CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL9341811 0.74 GAA (0.48) CA12CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL18495722 0.74 CA2 (0.44) CA12CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL5212059 0.71 GAA (0.48) CA12CA2CA9ALDH1A1SMN1; SMN2
SCHEMBL14997971 0.70 CA1 (0.44) CA12CA2CA9ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622891-B2 AMP-activated protein kinase activator KYOTO PHARMACEUTICAL UNIVERSITY (JP) 2026-05-12 US disclosed
US-12583887-B2 PSMA imaging agents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2026-03-24 US disclosed
US-12559521-B2 PSMA imaging agents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2026-02-24 US disclosed
US-20240425547-A1 PSMA Imaging Agents SIEMENS MEDICAL SOLUTIONS USA, INC. 2024-12-26 US disclosed
US-20240409580-A1 PSMA Imaging Agents SIEMENS MEDICAL SOLUTIONS USA, INC. 2024-12-12 US disclosed
US-12139554-B2 PSMA imaging agents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2024-11-12 US disclosed
US-12122851-B2 PSMA imaging agents SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2024-10-22 US disclosed
US-20240277657-A1 NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR KYOTO PHARMACEUTICAL UNIVERSITY (JP) 2024-08-22 US disclosed
EP-4349331-A1 NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR Kyoto Pharmaceutical University (JP) 2024-04-10 EP disclosed
WO-2022255499-A1 NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR 学校法人京都薬科大学 2022-12-08 WO disclosed
WO-2009134405-A2 NOVEL SUBSTRATE BASED PET IMAGING AGENTS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2009-11-05 WO disclosed
EP-2061519-A2 CLICK CHEMISTRY-DERIVED CYCLOPEPTIDE DERIVATIVES AS IMAGING AGENTS FOR INTEGRINS Siemens Medical Solutions USA, Inc. (US) 2009-05-27 EP disclosed
US-20090074664-A1 CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS SIEMENS MEDICAL SOLUTIONS USA, INC. 2009-03-19 US disclosed
WO-2009018175-A2 CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2009-02-05 WO disclosed
US-20080213175-A1 Click chemistry-derived cyclic peptidomimetics as integrin markers SIEMENS MEDICAL SOLUTIONS USA, INC. 2008-09-04 US disclosed
US-20080170992-A1 Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins SIEMENS MEDICAL SOLUTIONS USA, INC. 2008-07-17 US disclosed
WO-2008033561-A2 CLICK CHEMISTRY-DERIVED CYCLOPEPTIDE DERIVATIVES AS IMAGING AGENTS FOR INTEGRINS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2008-03-20 WO disclosed
WO-2008033557-A2 CLICK CHEMISTRY-DERIVED CYCLIC PEPTIDOMIMETICS AS INTEGRIN MARKERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2008-03-20 WO disclosed
US-4871868-A FROM AN ORGANIC HALIDE OR AN ARYL SULFONATE AND AN ALKALI METAL ACETYLIDE, 1,3-DIALKYL-2-IMIDAZOLIDINONE PROMOTER TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-10-03 US disclosed
EP-0284237-A1 Production of substituted acetylenic compounds Takeda Chemical Industries, Ltd. (JP) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425547-A1 PSMA Imaging Agents FOLH1, KLK3, PSMA2 CA12 40/4885CA2 1257/4885CA9 88/4885
US-20080213175-A1 Click chemistry-derived cyclic peptidomimetics as integrin markers ITGB1, ITGAM, ITGB3 CA12 437/4885CA2 3275/4885CA9 1212/4885
US-20240409580-A1 PSMA Imaging Agents FOLH1, KLK3, PSMA2 CA12 40/4885CA2 1257/4885CA9 88/4885
US-12559521-B2 PSMA imaging agents KLK3, PSMA1, PSMA6 CA12 20/4885CA2 153/4885CA9 18/4885
US-12139554-B2 PSMA imaging agents FOLH1, KLK3, PSMA2 CA12 40/4885CA2 1257/4885CA9 88/4885
US-12622891-B2 AMP-activated protein kinase activator PRKAA1, PRKAG1, PRKAB1 CA12 3529/4885CA2 703/4885CA9 1743/4885
US-20240277657-A1 NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR PRKAG1, PRKAG2, PRKAB1 CA12 4243/4885CA2 1398/4885CA9 3454/4885
US-12583887-B2 PSMA imaging agents KLK3, PSMA3, PSMA1 CA12 19/4885CA2 270/4885CA9 28/4885
US-20090074664-A1 CYCLIC AZAPEPTIDES AS INTEGRIN MARKERS ITGAV, ITGB3, ITGA2B CA12 438/4885CA2 4364/4885CA9 1167/4885
US-12122851-B2 PSMA imaging agents FOLH1, KLK3, PSMA2 CA12 40/4885CA2 1257/4885CA9 88/4885
US-20080170992-A1 Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins ITGB3, VCAM1, ITGB1 CA12 964/4885CA2 4010/4885CA9 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.